What Are Second-Line Treatments for Sarcoidosis?
At a Glance
When prednisone fails or causes severe side effects, doctors treat sarcoidosis with second-line steroid-sparing medications like methotrexate, azathioprine, or mycophenolate. If these disease-modifying drugs are ineffective, third-line biologic therapies like infliximab may be used.
In this answer
4 sections
If prednisone stops working, requires an uncomfortably high dose to keep your symptoms at bay, or causes side effects you can no longer tolerate, your doctor will likely recommend a steroid-sparing medication. These are typically disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, azathioprine, or mycophenolate mofetil [1][2]. If those second-line options are ineffective, doctors may escalate to third-line biologic therapies, such as infliximab or adalimumab, to get the inflammation under control [3][4].
Why Step Down from Steroids?
Corticosteroids like prednisone are the first-line defense against the inflammation of sarcoidosis [1][5]. However, up to 30% of patients require long-term, high-dose corticosteroids, which carry significant risks like weight gain, bone loss, and increased blood sugar [4][6][7].
Approximately 20% to 40% of patients experience treatment failure or severe intolerance to corticosteroids [8]. When the disease cannot be controlled without high doses, or when tapering the steroid dose causes symptoms to flare, doctors transition to second-line therapies. The goal is to maintain disease control while safely lowering or completely stopping your steroid dose [5][9].
How the Transition Works
Because second-line medications can take 3 to 6 months to reach their full effect, you will not stop prednisone abruptly. Instead, you will take both medications together for a period of time [4]. Once the new medication begins to work, your doctor will guide you through a slow, safe tapering process to minimize the risk of a flare.
Second-Line Therapies: Steroid-Sparing Agents
These medications are immunosuppressants that calm the overactive immune system responsible for forming granulomas (clusters of inflammatory cells characteristic of sarcoidosis).
Methotrexate
Methotrexate (MTX) is the most frequently prescribed second-line agent for sarcoidosis [10][9]. It is widely recognized for its strong steroid-sparing capabilities and is effective across many forms of the disease, including lung and heart involvement [11][12].
- Daily Side Effects: Unlike the weight gain and insomnia of steroids, methotrexate is more likely to cause day-to-day side effects like nausea, fatigue, or mouth sores [13].
- Required Co-Medication: To prevent these side effects and protect your liver, your doctor will prescribe a daily or weekly folic acid supplement [14].
- Monitoring: It requires regular blood tests to monitor for potential adverse effects, primarily involving liver health (such as liver fibrosis) and blood counts [15][16].
Azathioprine and Mycophenolate Mofetil
Azathioprine (AZA) and mycophenolate mofetil (MMF) are alternative immunosuppressants used if methotrexate is ineffective or if a patient cannot tolerate it. Both are widely used off-label as steroid-sparing agents. In medicine, off-label simply means the FDA initially approved the drug for a different condition (like organ transplant), but using them for sarcoidosis is standard, legal, and common practice in rheumatology [17].
Day-to-day side effects for these medications can include upset stomach, fatigue, and an increased risk of routine infections. While effective, some studies suggest that methotrexate might have a slight edge in efficiency over these alternatives for specific disease manifestations, like certain types of eye involvement [18].
Antimalarials and Leflunomide
Other medications are occasionally utilized depending on the specific organs affected by your sarcoidosis [1]:
- Antimalarial drugs (like hydroxychloroquine) are often used for skin or joint involvement. They require routine eye exams to monitor for a rare but serious risk of retinal toxicity [19].
- Leflunomide is another DMARD option that functions similarly to methotrexate [20].
Important Pregnancy Warning: Medications like methotrexate, mycophenolate mofetil, and leflunomide are highly teratogenic, meaning they can cause severe birth defects [1]. Strict birth control is required for both men and women of childbearing age while taking these drugs.
Third-Line Therapies: Biologics
If standard steroid-sparing agents fail to control the disease—a state called refractory sarcoidosis—doctors may escalate to third-line biologic therapies [9][21]. These advanced drugs specifically target and block a protein called tumor necrosis factor-alpha (TNF-α), which plays a key role in driving sarcoidosis inflammation.
Infliximab and Adalimumab
- Infliximab is given as an intravenous (IV) infusion and is highly effective for severe, refractory cases, including neurologic, cutaneous (skin), cardiac, and multisystem disease [22][23]. Because it is given via IV, it can sometimes cause immediate flu-like infusion reactions during the appointment.
- Adalimumab is administered as a subcutaneous (under the skin) injection. It is especially useful for skin and eye manifestations, and is frequently used as an alternative for patients who do not tolerate infliximab or fail to see results from it [24][25].
Mandatory Screening and Risks:
While TNF-alpha inhibitors successfully treat about two-thirds of patients with severe sarcoidosis, they strongly suppress the immune system and increase the risk of serious infections [26]. Before starting a biologic, mandatory pre-treatment blood tests are required to screen for latent tuberculosis (TB) and Hepatitis B, as these drugs can cause dormant infections to reactivate [27].
Looking Ahead: Emerging Treatments
For individuals who do not respond to biologics, researchers are investigating novel therapies. These include JAK inhibitors and mTOR inhibitors (like sirolimus), which target different parts of the immune system pathway and are currently being studied for refractory cases [28][29].
Common questions in this guide
How do I transition from prednisone to a second-line sarcoidosis medication?
What is the most common second-line treatment for sarcoidosis?
When are biologic therapies used for sarcoidosis?
Is it safe to get pregnant while taking second-line sarcoidosis medications?
Are medications like azathioprine officially approved for sarcoidosis?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given the specific organs my sarcoidosis affects, which second-line medication has the strongest track record?
- 2.What baseline testing, such as liver function, tuberculosis screening, or eye exams, do I need before starting a new immunosuppressant?
- 3.What is a realistic timeline to expect a reduction in my prednisone dose once we start a steroid-sparing agent, and how exactly will we overlap the medications?
- 4.How frequently will I need bloodwork to monitor for side effects on this new medication?
- 5.Are there any specific supplements, like folic acid, that I must take to safely manage the side effects of this treatment?
- 6.If this second-line drug does not work, what are the specific criteria we will use to decide when to move to a biologic therapy?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (29)
- 1
Rheumatic Manifestations of Sarcoidosis.
Day J, Hamann PDH
Diagnostics (Basel, Switzerland) 2024; (14(24)) doi:10.3390/diagnostics14242842.
PMID: 39767202 - 2
[Update on the treatment of sarcoidosis].
Rochat TS, Janssens JP, Soccal PM, Adler D
Revue medicale suisse 2016; (12(539)):1966-1971.
PMID: 28696638 - 3
Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, et al.
Seminars in arthritis and rheumatism 2015; (45(3)):361-8.
PMID: 26092330 - 4
Sarcoidosis-Related Uveitis: A Review.
Giorgiutti S, Jacquot R, El Jammal T, et al.
Journal of clinical medicine 2023; (12(9)) doi:10.3390/jcm12093194.
PMID: 37176633 - 5
Neurosarcoidosis and Neurologic Complications of Sarcoidosis Treatment.
Voortman M, Drent M, Stern BJ
Clinics in chest medicine 2024; (45(1)):91-103 doi:10.1016/j.ccm.2023.08.005.
PMID: 38245373 - 6
Treatment of Sarcoidosis.
Wijsenbeek MS, Culver DA
Clinics in chest medicine 2015; (36(4)):751-67.
PMID: 26593147 - 7
A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders.
Wells AU, Lower EE, Baughman RP, et al.
The Lancet. Respiratory medicine 2026; (14(4)):363-374 doi:10.1016/S2213-2600(25)00338-8.
PMID: 41207318 - 8
Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents.
Sharp M, Donnelly SC, Moller DR
Respiratory medicine: X 2019; (1()) doi:10.1016/j.yrmex.2019.100004.
PMID: 31187094 - 9
Refractory Sarcoidosis: A Review.
El Jammal T, Jamilloux Y, Gerfaud-Valentin M, et al.
Therapeutics and clinical risk management 2020; (16()):323-345 doi:10.2147/TCRM.S192922.
PMID: 32368072 - 10
Comparative effectiveness of disease-modifying antirheumatic drugs for patients with cardiac sarcoidosis.
Brooks L, Kivlin W, Mohananey D, et al.
Rheumatology (Oxford, England) 2025; (64(6)):3303-3308 doi:10.1093/rheumatology/keae692.
PMID: 39724230 - 11
A case report of steroid resistant cardiac sarcoidosis successfully managed with methotrexate.
Grabowska O, Martusewicz-Boros MM, Piotrowska-Kownacka D, Wiatr E
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2018; (35(2)):178-181 doi:10.36141/svdld.v35i2.6554.
PMID: 32476900 - 12
First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate.
Kahlmann V, Janssen Bonás M, Moor CC, et al.
The New England journal of medicine 2025; (393(3)):231-242 doi:10.1056/NEJMoa2501443.
PMID: 40387020 - 13
Methotrexate as a Steroid-Sparing Agent in Myasthenia Gravis: A Preliminary Retrospective Study.
Rodolico C, Bonanno C, Brizzi T, et al.
Journal of clinical neuromuscular disease 2021; (23(2)):61-65 doi:10.1097/CND.0000000000000342.
PMID: 34808648 - 14
Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?
Tavakolpour S
International immunopharmacology 2017; (53()):133-142 doi:10.1016/j.intimp.2017.10.027.
PMID: 29107213 - 15
Assessment of liver fibrosis markers in people with rheumatoid arthritis on methotrexate.
Olsson-White DA, Olynyk JK, Ayonrinde OT, et al.
Internal medicine journal 2022; (52(4)):566-573 doi:10.1111/imj.15125.
PMID: 33135387 - 16
Prevalence of liver fibrosis by Fibroscan in patients on long-term methotrexate therapy for rheumatoid arthritis.
Bafna P, Sahoo RR, Hazarika K, et al.
Clinical rheumatology 2021; (40(9)):3605-3613 doi:10.1007/s10067-021-05678-8.
PMID: 33686476 - 17
Current Perspectives on the Systemic Management of Atopic Dermatitis.
Davari DR, Nieman EL, McShane DB, Morrell DS
Journal of asthma and allergy 2021; (14()):595-607 doi:10.2147/JAA.S287638.
PMID: 34103945 - 18
Methotrexate versus conventional disease-modifying antirheumatic drugs in the treatment of non-anterior sarcoidosis-associated uveitis.
Leclercq M, Sève P, Biard L, et al.
The British journal of ophthalmology 2024; (109(1)):34-40 doi:10.1136/bjo-2024-325163.
PMID: 39013629 - 19
Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.
Friedman MA, Le B, Stevens J, et al.
Lung 2021; (199(2)):147-153 doi:10.1007/s00408-021-00436-8.
PMID: 33825964 - 20
Utility of Mechanistic Target of Rapamycin Inhibitors in Cardiac Sarcoidosis.
Richards D, Fujito H, Shanbhag A, et al.
Journal of cardiac failure 2025; (31(7)):1032-1036 doi:10.1016/j.cardfail.2024.10.444.
PMID: 39615743 - 21
Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia.
Rotenberg C, Besnard V, Brillet PY, et al.
The European respiratory journal 2018; (52(6)) doi:10.1183/13993003.01482-2018.
PMID: 30361243 - 22
Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis.
Sakkat A, Cox G, Khalidi N, et al.
Respiratory research 2022; (23(1)):54 doi:10.1186/s12931-022-01971-5.
PMID: 35264154 - 23
Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: A meta-analysis.
Rezaee M, Zangiabadian M, Soheili A, et al.
European journal of internal medicine 2023; (109()):42-49 doi:10.1016/j.ejim.2022.12.003.
PMID: 36526497 - 24
Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety.
Adler BL, Wang CJ, Bui TL, et al.
Seminars in arthritis and rheumatism 2019; (48(6)):1093-1104 doi:10.1016/j.semarthrit.2018.10.005.
PMID: 30446173 - 25
Biologic Therapy in the Treatment of Cutaneous Sarcoidosis: A Literature Review.
Dai C, Shih S, Ansari A, et al.
American journal of clinical dermatology 2019; (20(3)):409-422 doi:10.1007/s40257-019-00428-8.
PMID: 30895525 - 26
Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients.
Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, et al.
Seminars in arthritis and rheumatism 2017; (47(2)):288-294 doi:10.1016/j.semarthrit.2017.03.005.
PMID: 28392046 - 27
Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases.
Heidelberger V, Ingen-Housz-Oro S, Marquet A, et al.
JAMA dermatology 2017; (153(7)):681-685 doi:10.1001/jamadermatol.2017.1162.
PMID: 28564695 - 28
Infliximab-Induced Pulmonary Sarcoidosis Treated With Upadacitinib: A Case Report and Review of the Literature.
Swe E, Begun J
Cureus 2025; (17(4)):e82002 doi:10.7759/cureus.82002.
PMID: 40351964 - 29
Use of Sirolimus, an mTOR Inhibitor, to Treat Sarcoidosis in Multiple Systems.
McGuire L, Brown R, Asimaki A
Journal of cardiovascular translational research 2025; (18(6)):1893-1901 doi:10.1007/s12265-025-10700-4.
PMID: 40996589
This page provides educational information about second-line sarcoidosis treatments. Always consult your rheumatologist or specialist before stopping prednisone or starting new immunosuppressant medications.
Get notified when new evidence is published on Sarcoidosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.